Details of the Drug

General Information of Drug (ID: DM6AUFY)

Drug Name

Iloperidone

Synonyms

Fanapt; Fanapta; Fiapta; Zomaril; HP 873; Fanapt (TN); HP-873; ILO-522; Iloperidone [USAN:INN]; Fanapta, Zomaril, Iloperidone; Iloperidone (USAN/INN); 1-[4-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propoxy]-3-methoxyphenyl]ethanone; 4'-(3-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)propoxy)-3'-methoxyacetophenone

Indication

Disease Entry	ICD 11	Status	REF
Schizophrenia	6A20	Approved	[1]
------------------------------------------------------------------------------------

Affected Organisms

Humans and other mammals

ATC Code

N05AX14: Iloperidone

N05AX: Other antipsychotics

N05A: ANTIPSYCHOTICS

N05: PSYCHOLEPTICS

N: NERVOUS SYSTEM

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

426.5

Logarithm of the Partition Coefficient (xlogp)

4.1

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption Tmax: The time to maximum plasma concentration (Tmax) is 2-4 h []
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [2]
Elimination: 0.5% of drug is excreted from urine in the unchanged form [2]
Half-life: The concentration or amount of drug in body reduced by one-half in 18 - 33 hours [3]
Metabolism: The drug is metabolized via the hepatic []
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.804 micromolar/kg/day [4]
Vd: The volume of distribution (Vd) of drug is 1340-2800 L []
Water Solubility: The ability of drug to dissolve in water is measured as 0.03 mg/mL [2]

Chemical Identifiers

Formula: C24H27FN2O4
IUPAC Name: 1-[4-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propoxy]-3-methoxyphenyl]ethanone
Canonical SMILES: CC(=O)C1=CC(=C(C=C1)OCCCN2CCC(CC2)C3=NOC4=C3C=CC(=C4)F)OC
InChI: InChI=1S/C24H27FN2O4/c1-16(28)18-4-7-21(23(14-18)29-2)30-13-3-10-27-11-8-17(9-12-27)24-20-6-5-19(25)15-22(20)31-26-24/h4-7,14-15,17H,3,8-13H2,1-2H3
InChIKey: XMXHEBAFVSFQEX-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 71360
ChEBI ID: CHEBI:65173
CAS Number: 133454-47-4
UNII: VPO7KJ050N
DrugBank ID: DB04946
TTD ID: D0M8VE
INTEDE ID: DR0856
ACDINA ID: D00323

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
5-HT 2A receptor (HTR2A)	TTJQOD7	5HT2A_HUMAN	Antagonist	[5]
Dopamine D2 receptor (D2R)	TTEX248	DRD2_HUMAN	Antagonist	[5]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)_{Main DME}	DE4LYSA	CP3A4_HUMAN	Substrate	[6]
Cytochrome P450 2D6 (CYP2D6)_{Main DME}	DECB0K3	CP2D6_HUMAN	Substrate	[6]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Substrate	[7]
Cytochrome P450 3A7 (CYP3A7)	DERD86B	CP3A7_HUMAN	Substrate	[7]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Bile salt export pump (ABCB11)	OTRU7THO	ABCBB_HUMAN	Gene/Protein Processing	[8]
Cytochrome P450 3A4 (CYP3A4)	OTQGYY83	CP3A4_HUMAN	Gene/Protein Processing	[9]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Schizophrenia

ICD Disease Classification

6A20

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Dopamine D2 receptor (D2R)	DTT	DRD2	2.50E-02	-0.08	-0.49
Cytochrome P450 3A5 (CYP3A5)	DME	CYP3A5	9.96E-01	-3.17E-03	-1.84E-02
Cytochrome P450 2D6 (CYP2D6)	DME	CYP2D6	7.30E-01	-1.91E-02	-1.41E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	1.04E-02	6.29E-02	3.54E-01

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Iloperidone

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Amisulpride	DMSJVAM	Major	Increased risk of prolong QT interval by the combination of Iloperidone and Amisulpride.	Schizophrenia [6A20]	[10]
Asenapine	DMSQZE2	Major	Increased risk of prolong QT interval by the combination of Iloperidone and Asenapine.	Schizophrenia [6A20]	[10]
-----------

Coadministration of a Drug Treating the Disease Different from Iloperidone (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of Iloperidone and Ivosidenib.	Acute myeloid leukaemia [2A60]	[10]
Midostaurin	DMI6E0R	Major	Increased risk of prolong QT interval by the combination of Iloperidone and Midostaurin.	Acute myeloid leukaemia [2A60]	[10]
Arn-509	DMT81LZ	Major	Increased risk of prolong QT interval by the combination of Iloperidone and Arn-509.	Acute myeloid leukaemia [2A60]	[10]
Gilteritinib	DMTI0ZO	Major	Increased risk of prolong QT interval by the combination of Iloperidone and Gilteritinib.	Acute myeloid leukaemia [2A60]	[10]
Oliceridine	DM6MDCF	Major	Increased risk of prolong QT interval by the combination of Iloperidone and Oliceridine.	Acute pain [MG31]	[10]
Mepyramine	DMB4SFH	Moderate	Additive anticholinergic effects by the combination of Iloperidone and Mepyramine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[11]
Phenyltoloxamine	DMKAEQW	Moderate	Additive anticholinergic effects by the combination of Iloperidone and Phenyltoloxamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[11]
Ivabradine	DM0L594	Major	Increased risk of ventricular arrhythmias by the combination of Iloperidone and Ivabradine.	Angina pectoris [BA40]	[12]
Bedaquiline	DM3906J	Major	Increased risk of prolong QT interval by the combination of Iloperidone and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[10]
Levalbuterol	DM5YBO1	Moderate	Increased risk of ventricular arrhythmias by the combination of Iloperidone and Levalbuterol.	Asthma [CA23]	[13]
Troleandomycin	DMUZNIG	Major	Decreased metabolism of Iloperidone caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[14]
Retigabine	DMGNYIH	Major	Increased risk of prolong QT interval by the combination of Iloperidone and Retigabine.	Behcet disease [4A62]	[10]
Cariprazine	DMJYDVK	Moderate	Additive anticholinergic effects by the combination of Iloperidone and Cariprazine.	Bipolar disorder [6A60]	[15]
Eribulin	DM1DX4Q	Major	Increased risk of prolong QT interval by the combination of Iloperidone and Eribulin.	Breast cancer [2C60-2C6Y]	[10]
Tucatinib	DMBESUA	Major	Decreased metabolism of Iloperidone caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[14]
Bosutinib	DMTI8YE	Major	Increased risk of prolong QT interval by the combination of Iloperidone and Bosutinib.	Breast cancer [2C60-2C6Y]	[10]
PF-04449913	DMSB068	Major	Increased risk of prolong QT interval by the combination of Iloperidone and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[10]
Olodaterol	DM62B78	Moderate	Increased risk of ventricular arrhythmias by the combination of Iloperidone and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[16]
Vilanterol	DMF5EK1	Moderate	Increased risk of ventricular arrhythmias by the combination of Iloperidone and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[13]
Indacaterol	DMQJHR7	Moderate	Increased risk of ventricular arrhythmias by the combination of Iloperidone and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[16]
Pasireotide	DMHM7JS	Major	Increased risk of prolong QT interval by the combination of Iloperidone and Pasireotide.	Cushing syndrome [5A70]	[10]
Osilodrostat	DMIJC9X	Major	Increased risk of prolong QT interval by the combination of Iloperidone and Osilodrostat.	Cushing syndrome [5A70]	[10]
Ivacaftor	DMZC1HS	Moderate	Decreased metabolism of Iloperidone caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[17]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Iloperidone caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[18]
OPC-34712	DMHG57U	Moderate	Additive anticholinergic effects by the combination of Iloperidone and OPC-34712.	Depression [6A70-6A7Z]	[15]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Iloperidone and Esketamine.	Depression [6A70-6A7Z]	[19]
Deutetrabenazine	DMUPFLI	Major	Additive antidopaminergic effects by the combination of Iloperidone and Deutetrabenazine.	Dystonic disorder [8A02]	[20]
Ingrezza	DMVPLNC	Major	Increased risk of prolong QT interval by the combination of Iloperidone and Ingrezza.	Dystonic disorder [8A02]	[10]
Mirabegron	DMS1GYT	Moderate	Decreased metabolism of Iloperidone caused by Mirabegron mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[21]
Boceprevir	DMBSHMF	Major	Decreased metabolism of Iloperidone caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[14]
Telaprevir	DMMRV29	Major	Decreased metabolism of Iloperidone caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[14]
Fostemsavir	DM50ILT	Major	Increased risk of prolong QT interval by the combination of Iloperidone and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[10]
Cobicistat	DM6L4H2	Major	Decreased metabolism of Iloperidone caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[14]
Rilpivirine	DMJ0QOW	Major	Increased risk of prolong QT interval by the combination of Iloperidone and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[10]
Levamlodipine	DM92S6N	Moderate	Additive hypotensive effects by the combination of Iloperidone and Levamlodipine.	Hypertension [BA00-BA04]	[22]
TAK-491	DMCF6SX	Moderate	Additive hypotensive effects by the combination of Iloperidone and TAK-491.	Hypertension [BA00-BA04]	[22]
Givosiran	DM5PFIJ	Moderate	Decreased metabolism of Iloperidone caused by Givosiran mediated inhibition of CYP450 enzyme.	Inborn porphyrin/heme metabolism error [5C58]	[23]
Belladonna	DM2RBWK	Moderate	Additive anticholinergic effects by the combination of Iloperidone and Belladonna.	Infectious gastroenteritis/colitis [1A40]	[15]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Iloperidone caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[24]
ITI-007	DMUQ1DO	Moderate	Additive anticholinergic effects by the combination of Iloperidone and ITI-007.	Insomnia [7A00-7A0Z]	[15]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of ventricular arrhythmias by the combination of Iloperidone and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[10]
Glycerol phenylbutyrate	DMDGRQO	Moderate	Decreased metabolism of Iloperidone caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme.	Liver disease [DB90-DB9Z]	[12]
Crizotinib	DM4F29C	Major	Increased risk of prolong QT interval by the combination of Iloperidone and Crizotinib.	Lung cancer [2C25]	[10]
Ceritinib	DMB920Z	Major	Increased risk of prolong QT interval by the combination of Iloperidone and Ceritinib.	Lung cancer [2C25]	[10]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Iloperidone caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[25]
Dacomitinib	DMOH8VY	Major	Decreased metabolism of Iloperidone caused by Dacomitinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[14]
Osimertinib	DMRJLAT	Major	Increased risk of prolong QT interval by the combination of Iloperidone and Osimertinib.	Lung cancer [2C25]	[10]
Selpercatinib	DMZR15V	Major	Increased risk of prolong QT interval by the combination of Iloperidone and Selpercatinib.	Lung cancer [2C25]	[10]
Lumefantrine	DM29GAD	Major	Increased risk of prolong QT interval by the combination of Iloperidone and Lumefantrine.	Malaria [1F40-1F45]	[19]
Inotuzumab ozogamicin	DMAC130	Major	Increased risk of prolong QT interval by the combination of Iloperidone and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[10]
Idelalisib	DM602WT	Major	Decreased metabolism of Iloperidone caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[14]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Iloperidone caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[26]
Vemurafenib	DM62UG5	Major	Increased risk of prolong QT interval by the combination of Iloperidone and Vemurafenib.	Melanoma [2C30]	[10]
LGX818	DMNQXV8	Major	Increased risk of prolong QT interval by the combination of Iloperidone and LGX818.	Melanoma [2C30]	[10]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Iloperidone caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[12]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Iloperidone and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[27]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Iloperidone and Lasmiditan.	Migraine [8A80]	[28]
Panobinostat	DM58WKG	Major	Increased risk of prolong QT interval by the combination of Iloperidone and Panobinostat.	Multiple myeloma [2A83]	[10]
Siponimod	DM2R86O	Major	Increased risk of ventricular arrhythmias by the combination of Iloperidone and Siponimod.	Multiple sclerosis [8A40]	[19]
Fingolimod	DM5JVAN	Major	Increased risk of ventricular arrhythmias by the combination of Iloperidone and Fingolimod.	Multiple sclerosis [8A40]	[10]
Ozanimod	DMT6AM2	Major	Increased risk of prolong QT interval by the combination of Iloperidone and Ozanimod.	Multiple sclerosis [8A40]	[10]
Romidepsin	DMT5GNL	Major	Increased risk of prolong QT interval by the combination of Iloperidone and Romidepsin.	Mycosis fungoides [2B01]	[10]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Iloperidone caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[12]
Rolapitant	DM8XP26	Moderate	Decreased metabolism of Iloperidone caused by Rolapitant mediated inhibition of CYP450 enzyme.	Nausea/vomiting [MD90]	[29]
Entrectinib	DMMPTLH	Major	Increased risk of prolong QT interval by the combination of Iloperidone and Entrectinib.	Non-small cell lung cancer [2C25]	[10]
Lofexidine	DM1WXA6	Major	Increased risk of prolong QT interval by the combination of Iloperidone and Lofexidine.	Opioid use disorder [6C43]	[10]
Rucaparib	DM9PVX8	Major	Increased risk of prolong QT interval by the combination of Iloperidone and Rucaparib.	Ovarian cancer [2C73]	[10]
Triclabendazole	DMPWGBR	Major	Increased risk of prolong QT interval by the combination of Iloperidone and Triclabendazole.	Parasitic worm infestation [1F90]	[10]
Opicapone	DM1BKA6	Moderate	Antagonize the effect of Iloperidone when combined with Opicapone.	Parkinsonism [8A00]	[30]
Pimavanserin	DMR7IVC	Major	Increased risk of prolong QT interval by the combination of Iloperidone and Pimavanserin.	Parkinsonism [8A00]	[10]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Iloperidone caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[31]
Methylscopolamine	DM5VWOB	Moderate	Additive anticholinergic effects by the combination of Iloperidone and Methylscopolamine.	Peptic ulcer [DA61]	[15]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Iloperidone and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[32]
Lefamulin	DME6G97	Major	Increased risk of prolong QT interval by the combination of Iloperidone and Lefamulin.	Pneumonia [CA40]	[33]
Lonafarnib	DMGM2Z6	Major	Decreased metabolism of Iloperidone caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[14]
Degarelix	DM3O8QY	Major	Increased risk of prolong QT interval by the combination of Iloperidone and Degarelix.	Prostate cancer [2C82]	[10]
ABIRATERONE	DM8V75C	Major	Increased risk of prolong QT interval by the combination of Iloperidone and ABIRATERONE.	Prostate cancer [2C82]	[10]
Enzalutamide	DMGL19D	Major	Increased risk of prolong QT interval by the combination of Iloperidone and Enzalutamide.	Prostate cancer [2C82]	[10]
Relugolix	DMK7IWL	Major	Increased risk of prolong QT interval by the combination of Iloperidone and Relugolix.	Prostate cancer [2C82]	[10]
Neupro	DMHEAB1	Moderate	Antagonize the effect of Iloperidone when combined with Neupro.	Restless legs syndrome [7A80]	[30]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Iloperidone caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[19]
Vandetanib	DMRICNP	Major	Increased risk of prolong QT interval by the combination of Iloperidone and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[10]
Triptorelin	DMTK4LS	Major	Increased risk of prolong QT interval by the combination of Iloperidone and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[10]
Pitolisant	DM8RFNJ	Major	Increased risk of prolong QT interval by the combination of Iloperidone and Pitolisant.	Somnolence [MG42]	[10]
Telavancin	DM58VQX	Major	Increased risk of prolong QT interval by the combination of Iloperidone and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[10]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Iloperidone caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[34]
Lenvatinib	DMB1IU4	Major	Increased risk of prolong QT interval by the combination of Iloperidone and Lenvatinib.	Thyroid cancer [2D10]	[10]
Cabozantinib	DMIYDT4	Major	Increased risk of prolong QT interval by the combination of Iloperidone and Cabozantinib.	Thyroid cancer [2D10]	[10]
Acrivastine	DMTIGA0	Moderate	Additive anticholinergic effects by the combination of Iloperidone and Acrivastine.	Vasomotor/allergic rhinitis [CA08]	[15]
-----------


⏷ Show the Full List of 89 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Crospovidone	E00626	Not Available	Disintegrant
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium bicarbonate	E00424	516892	Alkalizing agent; Diluent
Water	E00035	962	Solvent
--------------------


⏷ Show the Full List of 6 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Iloperidone 1 mg tablet	1 mg	Oral Tablet	Oral
Iloperidone 10 mg tablet	10 mg	Oral Tablet	Oral
Iloperidone 12 mg tablet	12 mg	Oral Tablet	Oral
Iloperidone 2 mg tablet	2 mg	Oral Tablet	Oral
Iloperidone 4 mg tablet	4 mg	Oral Tablet	Oral
Iloperidone 6 mg tablet	6 mg	Oral Tablet	Oral
Iloperidone 8 mg tablet	8 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 87).
2	BDDCS applied to over 900 drugs
3	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
5	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
6	Influences of CYP2D6*10 polymorphisms on the pharmacokinetics of iloperidone and its metabolites in Chinese patients with schizophrenia: a population pharmacokinetic analysis. Acta Pharmacol Sin. 2016 Nov;37(11):1499-1508.
7	Application of liquid chromatography/mass spectrometry in accelerating the identification of human liver cytochrome P450 isoforms involved in the metabolism of iloperidone. J Pharmacol Exp Ther. 1998 Sep;286(3):1285-93.
8	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicol Sci. 2013 Nov;136(1):216-41.
9	Asenapine and iloperidone decrease the expression of major cytochrome P450 enzymes CYP1A2 and CYP3A4 in human hepatocytes. A significance for drug-drug interactions during combined therapy. Toxicol Appl Pharmacol. 2020 Nov 1;406:115239. doi: 10.1016/j.taap.2020.115239. Epub 2020 Sep 14.
10	Canadian Pharmacists Association.
11	Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
12	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
13	Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
14	Product Information. Fanapt (iloperidone). Vanda Pharmaceuticals Inc, Rockville, MD.
15	Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
16	Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
17	Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
18	Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
19	Cerner Multum, Inc. "Australian Product Information.".
20	Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
21	Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
22	Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
23	Product Information. Givlaari (givosiran). Alnylam Pharmaceuticals, Cambridge, MA.
24	Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
25	Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
26	Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
27	Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
28	Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
29	Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
30	Mims RB, Scott CL, Modebe O, Bethune JE "Inhibition of L-dopa-induced growth hormone stimulation by pyridoxine and chlorpromazine." J Clin Endocrinol Metab 40 (1975): 256-9. [PMID: 1117978]
31	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
32	Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
33	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
34	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.